Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial
CONCLUSION: rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI.TRIAL REGISTRATION: www.ClinicalTrials.gov (NCT02835534).PMID:37265385 | DOI:10.1097/CM9.0000000000002731 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - June 2, 2023 Category: General Medicine Authors: Xingshan Zhao Yidan Zhu Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu S Source Type: research
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial
CONCLUSION: rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI.TRIAL REGISTRATION: www.ClinicalTrials.gov (NCT02835534).PMID:37265385 | DOI:10.1097/CM9.0000000000002731 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - June 2, 2023 Category: General Medicine Authors: Xingshan Zhao Yidan Zhu Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu S Source Type: research
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial
CONCLUSION: rhTNK-tPA was non-inferior to rt-PA in the effect of improving recanalization of the infarct-related artery, a validated surrogate of clinical outcomes, among Chinese patients with acute STEMI.TRIAL REGISTRATION: www.ClinicalTrials.gov (NCT02835534).PMID:37265385 | DOI:10.1097/CM9.0000000000002731 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - June 2, 2023 Category: General Medicine Authors: Xingshan Zhao Yidan Zhu Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu S Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Intravenous thrombolysis of ischemic stroke-Current status
Nervenarzt. 2023 May 30. doi: 10.1007/s00115-023-01500-9. Online ahead of print.ABSTRACTIntravenous thrombolysis (IVT) treatment with alteplase (rtPA) is an essential part of the routine treatment of patients with ischemic stroke since its introduction in the late 1990s. Rapid treatment is of essential importance. For patients with an unclear time window, various mismatch concepts have been established to identify salvageable brain tissue prior to IVT. Numerous official contraindications for rtPA are not evidence-based; for example, current data from observational studies show that systemic thrombolytic treatment is possib...
Source: Der Nervenarzt - May 30, 2023 Category: Neurology Authors: Peter Ringleb Gregor Bauer Jan Purrucker Source Type: research
Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study
ConclusionsThe results show that alteplase exposure was virtually identical for the formulations tested, and statistical evaluation demonstrated bioequivalence of the formulations. Both formulations of alteplase were well tolerated by the subjects at the single intravenous doses in the trial.Trial RegistrationTrial registration number: NCT04419493, 2019-004932-40 (EudraCT Number). (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - May 30, 2023 Category: Drugs & Pharmacology Source Type: research
Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke
This cohort study evaluates rates of symptomatic intracranial hemorrhage following stroke with tenecteplase vs alteplase. (Source: JAMA Neurology)
Source: JAMA Neurology - May 30, 2023 Category: Neurology Source Type: research
Bioequivalence of Intravenous Alteplase from Two Different Manufacturing Processes in Healthy Male Volunteers: Results from a Two-Stage, Adaptive-Design Study
ConclusionsThe results show that alteplase exposure was virtually identical for the formulations tested, and statistical evaluation demonstrated bioequivalence of the formulations. Both formulations of alteplase were well tolerated by the subjects at the single intravenous doses in the trial.Trial RegistrationTrial registration number: NCT04419493, 2019-004932-40 (EudraCT Number). (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - May 30, 2023 Category: Drugs & Pharmacology Source Type: research
Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke
This randomized clinical trial of individuals with ischemic stroke assesses the safety and efficacy of treatment with a dual plasminogen activator vs usual treatment with intravenous alteplase. (Source: JAMA Neurology)
Source: JAMA Neurology - May 22, 2023 Category: Neurology Source Type: research
Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion
CMAJ Open. 2023 May 16;11(3):E443-E450. doi: 10.9778/cmajo.20220096. Print 2023 May-Jun.ABSTRACTBACKGROUND: Recent randomized trials have suggested that endovascular thrombectomy (EVT) alone may provide similar functional outcomes as the current standard of care, EVT combined with intravenous alteplase treatment, for acute ischemic stroke secondary to large vessel occlusion. We conducted an economic evaluation of these 2 therapeutic options.METHODS: We constructed a decision analytic model with a hypothetical cohort of 1000 patients to assess the cost-effectiveness of EVT with intravenous alteplase treatment versus EVT alo...
Source: cmaj - May 16, 2023 Category: General Medicine Authors: Zhikang Ye Ting Zhou Mengmeng Zhang Junwen Zhou Feng Xie Michael D Hill Eric E Smith Jason W Busse Yi Zhang Ying Liu Xin Wang Zhuo Ma Zhuoling An Source Type: research
Cost-effectiveness of endovascular thrombectomy with alteplase versus endovascular thrombectomy alone for acute ischemic stroke secondary to large vessel occlusion
CMAJ Open. 2023 May 16;11(3):E443-E450. doi: 10.9778/cmajo.20220096. Print 2023 May-Jun.ABSTRACTBACKGROUND: Recent randomized trials have suggested that endovascular thrombectomy (EVT) alone may provide similar functional outcomes as the current standard of care, EVT combined with intravenous alteplase treatment, for acute ischemic stroke secondary to large vessel occlusion. We conducted an economic evaluation of these 2 therapeutic options.METHODS: We constructed a decision analytic model with a hypothetical cohort of 1000 patients to assess the cost-effectiveness of EVT with intravenous alteplase treatment versus EVT alo...
Source: cmaj - May 16, 2023 Category: General Medicine Authors: Zhikang Ye Ting Zhou Mengmeng Zhang Junwen Zhou Feng Xie Michael D Hill Eric E Smith Jason W Busse Yi Zhang Ying Liu Xin Wang Zhuo Ma Zhuoling An Source Type: research
